Cas No.: | 1385035-79-9 |
Chemical Name: | (Z)-4-((1S,3aR,5S,12aS)-9-((E)-3,7-dimethylocta-2,6-dien-1-yl)-8,10-dihydroxy-2,2-dimethyl-11-(3-methylbut-2-en-1-yl)-4,7-dioxo-1,2,5,7-tetrahydro-1,5-methanofuro[2,3-d]xanthen-3a(4H)-yl)-N-(2-ethoxyethyl)-2-methylbut-2-enamide |
Synonyms: | GNA-002 |
SMILES: | C(NCCOCC)(=O)/C(/C)=C\C[C@@]12OC(C)(C)[C@]([H])3C[C@@]([H])(C1=O)/C=C1\[C@@]23OC2=C(C\1=O)C(O)=C(C/C=C(\C)/CC/C=C(/C)\C)C(O)=C2C/C=C(/C)\C |
Formula: | C42H55NO8 |
M.Wt: | 701.901 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | GNA002 (GNA-002) is a gambogenic acid (GNA) derivative that specifically and covalently binds to Cys668 within the EZH2-SET domain, trigges EZH2 degradation (IC50=1.1 uM) through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination; GNA002 is a relatively more potent EZH2 interacting agent than GNA, significantly suppresses H3K27Me3 and effectively reactivated PRC2-silenced tumor suppressor genes. |